Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Sagimet Biosciences reported its second quarter 2026 financial results, highlighting strategic focus on dermatology with plans to initiate a Phase 3 clinical trial of denifanstat for moderate to severe acne in the U.S. in the second half of 2026. The company also secured $175 million in equity financing in April 2026 and holds cash and marketable s…